Good Tumor Response to Chemoradioimmunotherapy in dMMR/MSI-H Advanced Colorectal Cancer: A Case Series

Good Tumor Response to Chemoradioimmunotherapy in dMMR/MSI-H Advanced Colorectal Cancer: A Case Series

PurposeImmune checkpoint blockade has led to a significant improvement of patient survival in metastatic colorectal cancer (CRC) with DNA mismatch repair-deficiency (dMMR)/microsatellite instability-high (MSI-H). However, not all these patients are sensitive to monoimmunotherapy. We firstly presente...

Full description

Bibliographic Details
Main Authors:	Chengjing Zhou, Ting Jiang, Yajie Xiao, Qiaoxuan Wang, Zhifan Zeng, Peiqiang Cai, Yongtian Zhao, Zhikun Zhao, Dongfang Wu, Hanqing Lin, Chao Sun, Rong Zhang, Weiwei Xiao, Yuanhong Gao
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2021-12-01
Series:	Frontiers in Immunology
Subjects:	chemotherapy radiotherapy immunotherapy programmed cell death protein 1 inhibitor colorectal cancer
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2021.784336/full

Similar Items

Opportunities and challenges of immunotherapy for dMMR/MSI-H colorectal cancer
by: Qi Zhang, et al.
Published: (2023-10-01)

Challenges and Therapeutic Opportunities in the dMMR/MSI-H Colorectal Cancer Landscape
by: Núria Mulet-Margalef, et al.
Published: (2023-02-01)

Importance of lymph node immune responses in MSI-H/dMMR colorectal cancer
by: Koji Inamori, et al.
Published: (2021-05-01)

Neoadjuvant Immunotherapy for Patients with dMMR/MSI-High Gastrointestinal Cancers: A Changing Paradigm
by: Muhammet Ozer, et al.
Published: (2023-07-01)

Treatments after Immune Checkpoint Inhibitors in Patients with dMMR/MSI Metastatic Colorectal Cancer
by: Quang Loc Bui, et al.
Published: (2022-01-01)

High-Risk Features Are Prognostic in dMMR/MSI-H Stage II Colon Cancer
by: Amr Mohamed, et al.
Published: (2021-10-01)

An interpretable deep learning model for identifying the morphological characteristics of dMMR/MSI-H gastric cancer
by: Xueyi Zheng, et al.
Published: (2024-03-01)

Neoadjuvant Immunotherapy for MSI-H/dMMR Locally Advanced Colorectal Cancer: New Strategies and Unveiled Opportunities
by: Xuan Zhang, et al.
Published: (2022-03-01)

Diagnosis of Lynch Syndrome and Strategies to Distinguish Lynch-Related Tumors from Sporadic MSI/dMMR Tumors
by: Julie Leclerc, et al.
Published: (2021-01-01)

Review of PD-1/PD-L1 Inhibitors in Metastatic dMMR/MSI-H Colorectal Cancer
by: André F. Oliveira, et al.
Published: (2019-05-01)

Combination of AKT1 and CDH1 mutations predicts primary resistance to immunotherapy in dMMR/MSI-H gastrointestinal cancer
by: Hui Chen, et al.
Published: (2022-06-01)

The role of LTN1 in dMMR CRC
by: Smith, E
Published: (2024)

Treatment with checkpoint inhibitors in a metastatic colorectal cancer patient with molecular and immunohistochemical heterogeneity in MSI/dMMR status
by: Fotios Loupakis, et al.
Published: (2019-11-01)

Mutations of PI3K-AKT-mTOR pathway as predictors for immune cell infiltration and immunotherapy efficacy in dMMR/MSI-H gastric adenocarcinoma
by: Zhenghang Wang, et al.
Published: (2022-04-01)

Case report: Efficacy of immunotherapy as conversion therapy in dMMR/MSI-H colorectal cancer: a case series and review of the literature
by: María San-Román-Gil, et al.
Published: (2024-02-01)

Retrospective Analysis of the Correlation of MSI-h/dMMR Status and Response to Therapy for Endometrial Cancer: RAME Study, a Multicenter Experience
by: Valentina Tuninetti, et al.
Published: (2023-07-01)

Association of immune-related adverse events with the outcomes of immune checkpoint inhibitors in patients with dMMR/MSI-H metastatic colorectal cancer
by: Chiara Cremolini, et al.
Published: (2023-01-01)

A scoping review and meta-analysis on the prevalence of pan-tumour biomarkers (dMMR, MSI, high TMB) in different solid tumours
by: Yoon-Jung Kang, et al.
Published: (2022-11-01)

DNA mismatch repair deficient (dMMR) endometrial cancer
by: Chia-Hao Liu, et al.
Published: (2022-09-01)

Real-world treatment patterns and clinical outcomes for chemotherapy-based regimens in first-line MSI-H/dMMR metastatic colorectal cancer
by: Mayur M. Amonkar, et al.
Published: (2023-01-01)

Development of a whole-slide-level segmentation-based dMMR/pMMR deep learning detector for colorectal cancer
by: Zhou Tong, et al.
Published: (2023-12-01)

Review of the application of dMMR and microsatellite instability in the diagnosis and treatment of endometrial cancer
by: Guangjie Liao, et al.
Published: (2021-01-01)

Efficacy and Safety of Neoadjuvant Monoimmunotherapy With PD-1 Inhibitor for dMMR/MSI⁃H Locally Advanced Colorectal Cancer: A Single-Center Real-World Study
by: Xuan Zhang, et al.
Published: (2022-07-01)

An unusual case of microsatellite instability–high/deficient mismatch repair (MSI-H/dMMR) diffuse large B-cell lymphoma revealed by targeted gene sequencing
by: Bogyeong Han, et al.
Published: (2022-03-01)

Hyperprogressive Disease After Combined Anti-PD-L1 and Anti-CTLA-4 Immunotherapy for MSI-H/dMMR Gastric Cancer: A Case Report
by: Romain Varnier, et al.
Published: (2021-09-01)

Neoadjuvant chemotherapy and radiotherapy followed by resection/ablation in stage IV rectal cancer patients with potentially resectable metastases
by: Rongzhen Li, et al.
Published: (2021-12-01)

Developments in Checkpoint Inhibitor Therapy for the Management of Deficient Mismatch Repair (dMMR) Rectal Cancer
by: Alan Su, et al.
Published: (2023-03-01)

Prognostic value of Lynch syndrome, BRAFV600E, and RAS mutational status in dMMR/MSI‐H metastatic colorectal cancer in a pooled analysis of Dutch and French cohorts
by: Koen Zwart, et al.
Published: (2023-08-01)

Locally advanced rectal cancer with dMMR/MSI-H may be excused from surgery after neoadjuvant anti-PD-1 monotherapy: a multiple-center, cohort study
by: Renfang Yang, et al.
Published: (2023-06-01)

P02.07 Trial in progress: anti-PD1, capecitabine, and oxaliplatin for the first-line treatment of dMMR esophagogastric cancer (AuspiCiOus-dMMR): a proof-of-principle study (AuspiCiOus)
by: HWM van Laarhoven, et al.
Published: (2024-03-01)

Survival outcomes in locally advanced dMMR rectal cancer: surgery plus adjunctive treatment vs. surgery alone
by: Kemin Ni, et al.
Published: (2023-10-01)

7 Local and peripheral response to pembrolizumab ± radiotherapy in rhesus macaques with naturally-occurring dMMR colorectal cancer
by: Simon Deycmar, et al.
Published: (2023-11-01)

Outcomes and toxicities of immune checkpoint inhibitors in colorectal cancer: a real‐world retrospective analysis
by: Chengjing Zhou, et al.
Published: (2021-09-01)

Efficacy and Safety of Camrelizumab in Combination with Docetaxel + S-1 Sequenced by Camrelizumab + S-1 for Stage III (PD-1+/MSI-H/EBV+/dMMR) Gastric Cancer: Study Protocol for a Single-Center, Prospective, Open-Label, Single-Arm Trial
by: Zhongyi Dong, et al.
Published: (2022-06-01)

Anus preservation in low rectal adenocarcinoma based on MMR/MSI status (APRAM): a study protocol for a randomised, controlled, open-label, multicentre phase III trial
by: Cheng-Yi Huang, et al.
Published: (2024-01-01)

The Alteration of T-Cell Heterogeneity and PD-L1 Colocalization During dMMR Colorectal Cancer Progression Defined by Multiplex Immunohistochemistry
by: Hongkai Yan, et al.
Published: (2022-05-01)

Cost-effectiveness analysis of pembrolizumab versus chemotherapy as first-line treatment for mismatch-repair-deficient (dMMR) or microsatellite-instability-high (MSI-H) advanced or metastatic colorectal cancer from the perspective of the Chinese health-care system
by: Chen Zhu, et al.
Published: (2023-10-01)

268 A phase 1 study of retifanlimab (INCMGA00012), a PD-1 inhibitor, in patients with advanced solid tumors: preliminary results in recurrent MSI-high or dMMR endometrial cancer (POD1UM-101)
by: Ignace Vergote, et al.
Published: (2020-11-01)

PD-1 inhibitor treatment in a penile cancer patient with MMR/MSI status heterogeneity: A case report
by: YunYi Du, et al.
Published: (2022-11-01)

Activity of pembrolizumab and lenvatinib in mismatch repair deficient (dMMR) endometrial cancer patients who have failed pembrolizumab monotherapy: A case series
by: Peter G. Rose, et al.
Published: (2023-12-01)